JAK3 Knockout CAL-27 Polyclonal Cells are a CRISPR/Cas9-edited polyclonal knockout cell population derived from the human tongue squamous cell carcinoma cell line CAL-27, engineered for loss-of-function studies of the JAK3 gene. This model provides a versatile tool for dissecting JAK-STAT signaling pathways in an oral squamous cell carcinoma epithelial context, supplying a heterogeneous pool of edited cells that eliminates clonal bias while maintaining consistent target gene ablation.
CAL-27 is a well-characterized epithelial cell line isolated from a human tongue squamous cell carcinoma, widely used in head and neck cancer research due to its retention of key pathological features. This adherent model offers a relevant background for studying oncogenic signaling and therapeutic responses, and its JAK3 knockout derivative permits specific interrogation of cytokine-mediated processes in a tumorigenic context.
JAK3 encodes a non-receptor tyrosine kinase that associates with the common gamma chain (IL2RG), mediating signaling from cytokines IL-2, IL-4, IL-7, IL-9, IL-15, and IL-21. Upon receptor engagement, JAK3 cooperates with JAK1 to phosphorylate STAT5A, STAT5B, and STAT3, which then dimerize and translocate to the nucleus to transcriptionally regulate target genes including CCND1, BCL2, and SOCS family members. Negative regulation is exerted by SOCS1, SOCS3, and PTPN2. JAK3 disruption thus severs signal transduction from multiple cytokine receptors, impairing STAT-dependent programs governing proliferation and survival.
In the CAL-27 context, JAK3 knockout abrogates cytokine-induced JAK-STAT signaling, notably STAT5 phosphorylation, blocking downstream proliferative and anti-apoptotic signals often exploited in squamous cell carcinoma. This loss-of-function model is valuable for investigating JAK3-dependent tumor growth, apoptosis resistance, and crosstalk with other oncogenic pathways. The model also holds translational relevance given JAK3’s role in severe combined immunodeficiency, T-cell acute lymphoblastic leukemia, and autoimmune disorders, facilitating evaluation of JAK inhibitor selectivity in epithelial malignancies.
This polyclonal knockout population supports diverse applications such as functional genomics, cytokine signaling studies, and drug response assays. Target disruption can be confirmed by Western blotting for JAK3 and phospho-STAT5, RT-qPCR for JAK3 mRNA, or immunofluorescence. Functional impacts are assessed through flow cytometry (STAT5 phosphorylation), cell proliferation, and apoptosis assays, enabling detailed phenotypic characterization. These assays facilitate the dissection of JAK3-dependent mechanisms in squamous cell carcinoma and the evaluation of pharmacological inhibitors targeting the JAK-STAT axis. For additional information, please contact Ascent Research.
